<div class="headers"><div>Figure 2. Proportion of patients with UC who achieved the composite score RBS = 0 and SFS <1 in the overall ITT {A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations. ^Difference adjusted % change [VDZ - PBO] = % of VDZ patients who achieved the indicated subscore - % of PBO patients who achieved the indicated subscore. Lower 95% Cl limits >0 indicate statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Cl, confidence interval; NS, nonsignificance; PBO, placebo; RBS, rectal bleeding subscore; SFS, stool frequency subscore; VDZ, vedolizumab.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p class="">Figure 2. Proportion of patients with UC who achieved the composite score RBS = 0 and SFS <1 in the overall ITT {A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations. ^Difference adjusted % change [VDZ - PBO] = % of VDZ patients who achieved the indicated subscore - % of PBO patients who achieved the indicated subscore. Lower 95% Cl limits >0 indicate statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Cl, confidence interval; NS, nonsignificance; PBO, placebo; RBS, rectal bleeding subscore; SFS, stool frequency subscore; VDZ, vedolizumab.</p></td>
</tr>
</tbody>
</table>
